The trial enrolled 703 participants who had previously received one or more lines of systemic therapy.

Patients who had received only one prior line of systemic therapy showed a stronger trend for overall survival and ...

Things are going from bad to worse for the pharmaceutical giant.

A post-marketing trial finds the oral antiviral achieves effective blood concentrations in at-risk children aged 6 years or older with mild-to-moderate COVID.

The study was originally meant to be published in a CDC weekly report in March.

Louisiana party pundits break down results in key races from the Party Primary runoff ...

Volatility can lower the cost of entry into businesses that throw off real cash, even as investors recognize that a low share ...

The mRNA vaccines approved to treat COVID-19 are safe and effective and show promise in treating other diseases including ...

Pfizer (NYSE:PFE) oncology updates and IBRANCE expansion unfold within S&P 500 healthcare segment, alongside lung cancer ...

(NYSE: PFE) today announced the U.S. Food and Drug Administration (FDA) approved IBRANCE ® (palbociclib) in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the ...

It’s been seven years since Pfizer scored an expansion for its breast cancer blockbuster Ibrance, and during that time, the drug has started to lag sales of two others in its cl ...

A comprehensive new review published in The Lancet affirms that currently approved mRNA vaccines are safe and highly ...